Table 1.
Description of the participants contributing to the baseline and biopsy cohorts. (both cohorts consist of HPV positive women
| Baseline cohort (n = 1079 women) | Biopsy cohort (n = 201 women) * | |
|---|---|---|
| Age at cohort entry | ||
| 30–39 | 539 (50.0%) | 119 (59.2%) |
| 40–49 | 303 (28.1%) | 47 (23.4%) |
| 50–59 | 134 (12.4%) | 23 (11.4%) |
| 60–69 | 64 (5.9%) | 7 (3.5%) |
| 70+ | 39 (3.6%) | 5 (2.5%) |
| Smoking (at initial examination) | ||
| Never | 551 (51.1%) | 98 (48.8%) |
| Current | 384 (35.6%) | 82 (40.8%) |
| Ex | 110 (10.2%) | 21 (10.4%) |
| Unknown | 34 (3.1%) | 0 (0.0%) |
| Pap smear at cohort entry | ||
| Normal | 1079 (100%) | 142 (70.7%) |
| ASC-US | 0 | 23 (11.4%) |
| ASC-H | 0 | 3 (1.5%) |
| LSIL | 0 | 33 (16.4%) |
*All women in the biopsy cohorts are also included in the baseline cohort